Literature DB >> 12562559

Managing outpatient asthma exacerbations.

Sitesh R Roy1, Henry Milgrom.   

Abstract

Asthma is a chronic inflammatory disease that renders individuals prone to acute exacerbations. Several allergic and nonallergic triggers can incite an asthma exacerbation. The goals of managing an asthma exacerbation are prompt recognition, rapid reversal of airflow obstruction, prevention of relapses, and forestalling future episodes. A written asthma home-management plan is essential to minimize the severity of exacerbations. Short-acting b-agonists, oxygen, and corticosteroids are fundamental to early intervention in acute asthma exacerbation. Anticholinergics and magnesium sulfate can help nonresponders. Newer agents such as levalbuterol and long-acting b-agonists might be future additions to our armamentarium of drugs to treat acute exacerbations. Initiation or intensification of long-term controller therapy, treatment of co-morbid conditions, and avoidance of possible triggers along with prompt follow-up can help prevent relapses. Listening to patient preferences and concerns to enhance adherence and regular follow-up care can help prevent future episodes.

Entities:  

Mesh:

Year:  2003        PMID: 12562559     DOI: 10.1007/s11882-003-0032-7

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.919


  50 in total

1.  Levalbuterol and racemic albuterol: are there therapeutic differences?

Authors:  R Ahrens; M Weinberger
Journal:  J Allergy Clin Immunol       Date:  2001-11       Impact factor: 10.793

Review 2.  Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality?

Authors:  R Beasley; N Pearce; J Crane; C Burgess
Journal:  J Allergy Clin Immunol       Date:  1999-08       Impact factor: 10.793

3.  Tolerance to the bronchoprotective effect of beta2-agonists: comparison of the enantiomers of salbutamol with racemic salbutamol and placebo.

Authors:  D W Cockcroft; B E Davis; V A Swystun; D D Marciniuk
Journal:  J Allergy Clin Immunol       Date:  1999-06       Impact factor: 10.793

4.  The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients.

Authors:  J Lötvall; M Palmqvist; P Arvidsson; A Maloney; G P Ventresca; J Ward
Journal:  J Allergy Clin Immunol       Date:  2001-11       Impact factor: 10.793

Review 5.  Early use of inhaled corticosteroids in the emergency department treatment of acute asthma.

Authors:  Marcia L Edmonds; Stephen J Milan; Carlos A Camargo; Charles V Pollack; Brian H Rowe
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

6.  Inhaled flunisolide for acute severe asthma.

Authors:  G Rodrigo; C Rodrigo
Journal:  Am J Respir Crit Care Med       Date:  1998-03       Impact factor: 21.405

7.  Clinical features of vocal cord dysfunction.

Authors:  K B Newman; U G Mason; K B Schmaling
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

8.  Effect of nebulized ipratropium on the hospitalization rates of children with asthma.

Authors:  F Qureshi; J Pestian; P Davis; A Zaritsky
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

9.  Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid.

Authors:  J Garrett; S Williams; C Wong; D Holdaway
Journal:  Arch Dis Child       Date:  1998-07       Impact factor: 3.791

10.  Factors associated with relapse after emergency department treatment for acute asthma.

Authors:  C L Emerman; R K Cydulka
Journal:  Ann Emerg Med       Date:  1995-07       Impact factor: 5.721

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.